期刊文献+

兔下颌骨缺损修复中骨保护素及配体和环氧合酶-2的表达

Expression of osteoprotegerin, osteoprotegerin ligand and cyclooxygenase-2 in the repairing process of mandibular defect in rabbit
在线阅读 下载PDF
导出
摘要 目的:探讨骨保护素(Osteoprotegerin,OPG)、骨保护素配体(Osteoprotegerin ligand,OPGL)和环氧合酶-2(Cyclooxygenase-2,COX-2)在下颌骨缺损修复中的作用机制。方法:健康雄性新西兰大白兔48只,随机分为对照组(24只)和实验组(24只),建立下颌骨缺损模型,分别于建模后3、14、28、56d处死相同例数动物(n=6),然后收集下颌骨缺损处的骨组织块。采用免疫组织化学、RT-PCR技术检测OPG、OPGL、COX-2蛋白及mRNA表达变化。结果:兔下颌骨缺损修复过程中,OPG、OPGL、COX-2蛋白和mRNA在不同时间点均有不同程度高表达(P<0.05),但各指标峰值出现的时间点不同(P<0.01)。OPG,OPGL,COX-2峰值分别出现在建模后3、28、14d。结论:兔下颌骨缺损修复中OPG、OPGL、COX-2蛋白及mRNA表达水平不同程度高表达,提示其可能参与兔下颌骨缺损修复的过程。 Objective To explore the repair mechanism of osteoprotegerin (OPG), osteoprotegerin ligand (OPGL) and cyclooxygenase-2(COX-2) in mandibular defect. Methods 48 healthy male New Zealand rabbits were randomly divided into the control group (24) and the experimental group (24). On 3 d, 14 d, 28 d, 56 d after the mandibular defect modele was established, 6 rabbits were killed separately. At the same time, the bone in the zone of mandibular defect was collected. The expression of protein and mRNA including OPG, OPGL and COX-2 were tested by means of immunohistoehemical technique and RT-PCR. Results The protein and mRNA of OPG, OPGL and COX-2 were highly expressed to varying degrees at different time points (P 〈 0.05). However, the maximum peak of three indexes presented at different time points separately (P 〈 0.01 ). OPG, OPGL, COX-2 presented their each maximum peak on 3 d, 28 d, 14 d respectively after establishing model. Conclusion The protein and mRNA of OPG, OPGL and COX-2 were highly expressed to varying degrees at different time points, which can be concluded that they may oarticioate in the repairing process of the mandibular defect.
出处 《实用医学杂志》 CAS 北大核心 2011年第15期2712-2714,共3页 The Journal of Practical Medicine
关键词 骨保护素 骨保护素配体 环氧合酶-2 下颌骨缺损 Osteoprotegerin Osteoprotegerin ligand Cyclooxygenase-2 Mandibular defect
  • 相关文献

参考文献6

  • 1Pivonka P, Zimak J, Smith D W, et al. Model structure and control of bone remodeling: a theoretical study [J]. Bone, 2008,43 (2) : 249-263.
  • 2Fracon R N, Teofilo J M, Satin R B, et al. Prostaglandins and bone: potential risks and benefits related to the use of nonsteroidal anti-inflammatory drugs in clinical dentistry [J]. J Oral Sci, 2008,50(3) :247-252.
  • 3张军霞,向光大,孙慧伶,赵林双,侯洁.甲状腺激素对血管内皮细胞护骨素表达的影响[J].实用医学杂志,2010,26(7):1112-1114. 被引量:2
  • 4Kadow R A, Hoffmann J E, Duda G, et al. Effect of mechanical stimulation on osteoblast-and osteoelast-like ceils in vitro [J]. Ceils Tissues Organs, 2009,190(2):61-68.
  • 5Hakeda Y, Kobayashi Y, Yamaguchi H, et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone- resorbing activity of isolated mature osteoclasts [J]. Biochem Biophys Res Commun, 1998,251 (3) : 796-801.
  • 6Schwartz Z, Denison T A, Bannister S R, et al. Osteoblast response to fluid induced shear depends on substrate microarchitecture and varies with time [J]. J Biomed Mater Res A, 2007,83 ( 1 ) : 20-32.

二级参考文献15

  • 1Browner W S, Lui L Y, Cummings S R. Association of serum osteoprotegerln levels with diabetes, stroke, bonedensity, fractures, and mortality in elderly women [J]. J Clin Endocrinol Metab, 2001, 86(2) : 631-637.
  • 2Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction [J]. J Am Coll Cardiol,2004, 44(10) : 1970-1976.
  • 3Kim S M, Lee J, Ryu O H, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity [J]. Clin Endocrinol, 2005,63(5) :594-598.
  • 4Knudsen S T, Foss C H, Poulsen P L, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications [J]. Eur J Endocrinol,2003,149 (2) : 161.
  • 5Xiang G D, Xu L, Zhao L S, et al. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilatioan in type 2 diabetes [J]. Diabetes, 2006,55(7):2126-2131.
  • 6Taddei S, Caraccio N, Virdis A, et al. Impaired endotheliumdependent vasodilatation in subclinical hypothyroidism:beneficial effect of levothyroxine therapy [J]. J Clin Endocrinol Metab,2003, 88 (8) : 3731-3737.
  • 7Nagasaki T, Inaba M, Jono S, et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function [J]. Eur J Endocrinol,2005, 152(3) :347-353.
  • 8Carretero J I, Blasco F A, Milla J L, et al. Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women [J]. Eur J Endocrinol, 2007, 156(5) : 539-545.
  • 9Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in micelacking osteoclastogenesis inhibitory factor/osteoprotegerin [J]. Biochem Biophys Res Commun, 1998,247(3) :610-615.
  • 10Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor. increased serum concentrations in postmenopausal women with osteoporosis [J]. J Bone Miner Res, 1999,14(4) :518-527.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部